ArticleThe journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG2026
Assessment of Enteral Baclofen Prescribing Practices for Infants With Hypertonia.
Article in The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveBaclofen is used for hypertonia in infants despite limited dosing guidance. This study describes enteral baclofen prescribing in patients 12 months of age and younger.
methodsThis single-center, retrospective review evaluated infants receiving enteral baclofen from January 2013 to December 2022. Regimen information, including dose, frequency, age, weight, and duration of treatment for up to 1 year following initiation, was assessed. Other outcomes included place in therapy, safety, and tolerability.
resultsThis study included 108 patients with 423 total regimens. At initiation, the median baclofen dose was 1.3 mg, corresponding to a weight-based dose (WBD) of 0.2 mg/kg, a total daily dose (TDD) of 3 mg, and a weight-based total daily dose (wTDD) of 0.5 mg/kg/day. Sixty-one patients (56.5%) received baclofen 3 times daily at initiation. The patients' longest-tolerated regimen had a median dose of 2.8 mg, corresponding to a WBD of 0.4 mg/kg, a TDD of 9 mg, and a wTDD of 1.3 mg/kg/day. Hypoxemic-ischemic encephalopathy and brain injury were the most common etiologies of hypertonia. Baclofen was the first antispastic agent for 37 patients (34.3%). Twenty-four patients (22.2%) discontinued baclofen within 1 year. Four patients (3.7%) stopped baclofen due to adverse effects (sedation and emesis).
conclusionsThe median initiation dose of baclofen in infants was lower than the recommended dose for patients aged younger than 2 years, highlighting variability in practice. The baclofen regimens used in this study were safe and well-tolerated. These findings provide insight into baclofen prescribing for infants with hypertonia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.